Rite Aid (RAD) surges 30% higher as merger chances improve >>> READ MORE


Recent Articles

Play the iShares Nasdaq Biotechnology Index (ETF)’s (IBB) Popularity for Free

ETFs should not move 11% in four days. The IBB just did that, so I will short it with no money out of pocket. Bet against the herd mentality. More 

Is the SPDR S&P Biotech (ETF) (XBI) Done Running?

Biotech stocks are booming, but resistance looms close. Time to take profits on the SPDR S&P Biotech (ETF) XBI calls, but also consider reloading. More 

Trade of the Day: SPDR S&P Biotech (ETF) (XBI)

XBI hit a new 52-week high of $76.60 on Tuesday before easing back slightly to about $75. And I'm opting to employ one of my preferred bullish strategies here. More 

The SPDR S&P Biotech (ETF) (XBI) Is on Breakout Watch

Biotech stocks are quietly climbing higher. Here's how to trade the SPDR S&P Biotech (ETF) (XBI) before its seemingly imminent pop. More 

Direxion Daily S&P Biotech Bear 3X Shares (LABD): The Quick Guide to LABD

Like other leveraged ETFs, Direxion Daily S&P Biotech Bear 3X Shares (LABD) seduces with big potential gains when biotech stocks drop. More 

3 Biotech Trades for the Faux Doomsday Scenario

Biotech stocks have been a political football throughout the campaign and even now. Sell risk against the fear and the hope for a profit. More 

How to Profit From the Bulls’ Return to Biotech Stocks (XBI)

Biotech stocks are making a comeback. Use this bullish XBI play to capitalize on continued strength in the sector. More